TY - JOUR
AU - Kerr, Steven
AU - Vasileiou, Eleftheria
AU - Robertson, Chris
AU - Sheikh, Aziz
PY - 2022
DA - July
TI - COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2:Cohort and test-negative study of 5.4 million individuals in Scotland
JO - Journal of Global Health
IS - 12 
DO - https://doi.org/10.7189/jogh.12.05025
AB - Background: In July 2021, a new variant of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in the Delta lineage was detected in the United Kingdom (UK), named AY.4.2 or "Delta plus". By October 2021, the AY.4.2 variant accounted for approximately 10-11% of cases in the UK. AY.4.2 was designated as a variant under investigation by the UK Health and Security Agency on 20 October 2021. This study aimed to investigate vaccine effectiveness (VE) against symptomatic COVID-19 (Coronavirus disease 2019) infection and COVID-19 hospitalisation/death for the AY.4.2 variant.
PB - International Society of Global Health
UR - https://www.research.ed.ac.uk/en/publications/94040b59-9a81-4405-9210-ac9458f80401
KW - Coronavirus (COVID-19)
KW - Immunisation and screening
ER